D4 Labs, LLC announced today that it will present a paper entitled, “Immunogenicity and efficacy of a subcutaneously administered, adjuvanted vaccine containing modified S1 spike protein of SARS-CoV-2 variant C.1.2” at the fourth edition of the International Vaccines Congress in Baltimore, Maryland on October 24-26, 2024. The presentation deals with a new adjuvant system for vaccines called SubATVax™, which contains modified S1 spike protein sequences of the SARS-CoV-2 virus.

Dr. Wright, the Chief Scientific Officer at D4 Labs, LLC, stated: 
“This is the first subcutaneously-administered, adjuvanted subunit spike protein vaccine for SARS-CoV-2 which generates IgG, IgA, and IgM responses with one dose of vaccine. A booster dose generates higher titered antibody responses, which last for over 120 days in our hamster model. This vaccine is administered through a 25 gauge needle.”

D4 Labs received a U.S. Patent (#11911461) for its subcutaneously administered adjuvant, SubATVax™, using modified S1 spike protein of SARS-CoV-2 variant C.1.2. A paper describing the preclinical testing of this technology was published in bioRxiv in September 2023. 

For more information, please contact Dr. Wright (831) 664-5464

D4 Labs, LLC in Pacific Grove, CA announced today that it has successfully prepared an adjuvanted DTaP (inactivated Diphtheria toxoid, inactivated Tetanus toxoid, and acellular Pertussis) and inactivated Poliovirus vaccine combination using its SubATVax™ technology, utilizing the same formulation in its recently issued U.S. Patent #11911461.

Dr. David Craig Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:

“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. Several approved vaccines require up to five injections for optimal immunity. Two of those are the DTaP and Poliovirus vaccines used in the United States. We have successfully adjuvanted a combination vaccine containing DTaP and Poliovirus antigens with our SubATVax™ technology. Our SubATVax™ vaccines can be administered in small volumes (300 microliters) subcutaneously through 25-gauge needles. We have also filled needleless syringes with 250 microliters of our adjuvanted vaccines. We encourage other companies, government laboratories, and academic centers to contact us about utilizing our technology with either approved vaccines, like a DTaP and Poliovirus combination, or new vaccines in development.”

For more information, call Dr. Wright at (831) 664-5464 or email davidwright@d4labs.com

D4 Labs, LLC in Pacific Grove, CA announced today that it has successfully prepared an adjuvanted inactivated Diphtheria toxoid, Tetanus toxoid, and acellular Pertussis (DTaP) vaccine using its SubATVax™ technology, utilizing the same formulation in its recently issued U.S. Patent #11911461.

Dr. David Craig Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:
“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. Several approved vaccines require up to five injections for optimal immunity. One of those is the DTaP vaccine used in the United States. We have successfully adjuvanted a DTaP vaccine with our SubATVax™ technology. Our SubATVax™ vaccines can be administered in small volumes (300 microliters) subcutaneously through 25-gauge needles. We have also filled needleless syringes with 250 microliters of our adjuvanted vaccines. We encourage other companies, government laboratories, and academic
centers to contact us about utilizing our technology with either approved vaccines, like DTaP, or new vaccines in development.”

For more information, call Dr. Wright at (831) 664-5464 or email davidwright@d4labs.com

D4 Labs, LLC in Pacific Grove, CA announced today that it has successfully prepared an inactivated Poliovirus vaccine using its SubATVax™ technology, utilizing the same formulation in its recently issued U.S. Patent #11911461.

Dr. David Craig Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:
“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. Several approved vaccines require up to five injections for optimal immunity. One of those is the inactivated Poliovirus vaccine used in the United States. We have successfully adjuvanted an inactivated Poliovirus vaccine with our SubATVax™ technology. Our SubATVax™ vaccines can be administered in small volumes (300 microliters) subcutaneously through 25-gauge needles. We have also filled needleless syringes with 250 microliters of our adjuvanted vaccines. We encourage other companies, government laboratories, and academic centers to contact us about utilizing our technology with either approved vaccines, like inactivated Poliovirus, or new vaccines in development.”

For more information, call Dr. Wright at (831) 664-5464 or email davidwright@d4labs.com

D4 Labs, LLC in Pacific Grove, CA announced today that it has successfully prepared two Influenza vaccines using its SubATVax™ technology, utilizing the same formulation in its recently issued U.S. Patent #11911461.

Dr. David Craig Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:

“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. We have now utilized our SubATVax™ technology to prepare adjuvanted, trivalent and quadrivalent, split virus Influenza vaccines. Our SubATVax™ vaccines can be administered in small volumes (300 microliters) subcutaneously through 25-gauge needles. We have also filled needleless syringes with 250 microliters of our adjuvanted vaccines. We encourage other companies, government laboratories, and academic centers to contact us about utilizing our technology with either approved vaccines, like those for Influenza, or new vaccines in development.”

For more information, call Dr. Wright at (831) 664-5464 or email davidwright@d4labs.com

D4 Labs, LLC announced that it has received a U.S. Patent #11911461 for its subcutaneously administered adjuvant, SubATVax™, using modified sequences of the SARS-CoV-2 (COVID-19) S1 sequence. A paper describing the preclinical testing of this technology, when administered subcutaneously, was published in bioRxiv in September 2023. 

Dr. Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:

“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. The aforementioned patent and paper describe this work in detail. Additionally, we successfully completed a two-year stability study on this refrigerated, adjuvanted SARS-CoV-2 vaccine. We would encourage other companies, government laboratories, and academic centers to contact us about utilizing our technology with either approved vaccines or new vaccines in development.”

For more information, please contact Dr. Wright (831) 664-5464